Article metrics
PDF
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell - related adverse events
- Study protocol for THINK: a multinational open - label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
- Emerging immunotherapies in multiple myeloma
- Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
- Treatment of patients with relapsed or refractory CD19 + lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD 28.4-1BBzeta retroviral vector: a unicentre phase I / II clinical trial protocol
- Modulating TNFα activity allows transgenic IL15 - Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
- The Great Debate at ‘ Immunotherapy Bridge ’, Naples, December 5, 2019